Search
for
Sort by
Research 451–480 of 777
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
- Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- Ivarmacitinib stimulates hair regrowth in severe alopecia areata
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- Upadacitinib for the treatment of alopecia areata – A case report
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Citrullination at the Inflammatory Skin Barrier
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Spotlight in Plastic Surgery: October 2022
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- Tratamiento de la alopecia areata, un recorrido desde las opciones terapéuticas clásicas hasta los nuevos fármacos aparecidos en los últimos años
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo